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ABSTRACT
Objective To determine whether robot- assisted training 
is cost- effective compared with an enhanced upper limb 
therapy (EULT) programme or usual care.
Design Economic evaluation within a randomised 
controlled trial.
Setting Four National Health Service (NHS) centres in the 
UK: Queen’s Hospital, Barking, Havering and Redbridge 
University Hospitals NHS Trust; Northwick Park Hospital, 
London Northwest Healthcare NHS Trust; Queen Elizabeth 
University Hospital, NHS Greater Glasgow and Clyde; and 
North Tyneside General Hospital, Northumbria Healthcare 
NHS Foundation Trust.
Participants 770 participants aged 18 years or older with 
moderate or severe upper limb functional limitation from 
first- ever stroke.
Interventions Participants randomised to one of three 
programmes provided over a 12- week period: robot- 
assisted training plus usual care; the EULT programme 
plus usual care or usual care.
Main economic outcome measures Mean healthcare 
resource use; costs to the NHS and personal social 
services in 2018 pounds; utility scores based on EQ- 5D- 5L 
responses and quality- adjusted life years (QALYs). Cost- 
effectiveness reported as incremental cost per QALY and 
cost- effectiveness acceptability curves.
Results At 6 months, on average usual care was the 
least costly option (£3785) followed by EULT (£4451) with 
robot- assisted training being the most costly (£5387). 
The mean difference in total costs between the usual 
care and robot- assisted training groups (£1601) was 
statistically significant (p<0.001). Mean QALYs were 
highest for the EULT group (0.23) but no evidence of 
a difference (p=0.995) was observed between the 
robot- assisted training (0.21) and usual care groups 
(0.21). The incremental cost per QALY at 6 months for 
participants randomised to EULT compared with usual 
care was £74 100. Cost- effectiveness acceptability curves 
showed that robot- assisted training was unlikely to be 
cost- effective and that EULT had a 19% chance of being 
cost- effective at the £20 000 willingness to pay (WTP) 
threshold. Usual care was most likely to be cost- effective 
at all the WTP values considered in the analysis.
Conclusions The cost- effectiveness analysis suggested 
that neither robot- assisted training nor EULT, as delivered 
in this trial, were likely to be cost- effective at any of the 
cost per QALY thresholds considered.
Strengths and limitations of this study
 ► Our economic evaluation was designed and con-
ducted following best practice methods which re-
sulted in robust and generalisable results.
 ► Sensitivity analyses exploring any uncertainties sur-
rounding the level of resource use and their impact 
on the cost- effectiveness of the interventions add to 
the robustness of the results.
 ► The unavailability of longer- term data for the with-
in trial evaluation means that no robust inferences 
could be made on the long- term cost- effectiveness 
of the interventions.
 ► Poor completion of arm rehabilitation therapy logs 
meant that detailed information on the delivery of 
usual care was obtained from the health service util-
isation questionnaire.
 ► The use of quality- adjusted life years based on 
responses to the EQ- 5D- 5L questionnaire as a ge-
neric outcome measure may not accurately capture 
changes in quality of life for this patient group.
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Trial registration number ISRCTN69371850.
INTRODUCTION
Stroke is the fourth leading cause of death in the UK and 
a leading cause of disability. Almost two- thirds of patients 
who had a stroke leave hospital with a disability.1 A 
common disability following a stroke is loss of upper limb 
function. This results in a reduction of the individual’s 
autonomy and impedes activities of daily living. Approxi-
mately 80% of people with acute stroke have upper limb 
motor impairment, with 50% of patients still experiencing 
problems after 4 years following the stroke.2 3
The Robot- Assisted Training for the Upper Limb after 
Stroke (RATULS) trial sought to evaluate the clinical effec-
tiveness and cost- effectiveness of robot- assisted training 
(using the MIT- Manus robotic gym system) by comparing 
it with either an enhanced upper limb therapy (EULT) 
programme, or usual care.4 5 Participants in the robot- 
assisted training and EULT groups also received usual 
care. The robot- assisted training and EULT programmes 
were of the same duration and frequency (45 min face- 
to- face therapy, three times a week for 12 weeks). Results 
from the trial provided no evidence that robot- assisted 
training as delivered in the study nor EULT improved 
upper limb function after stroke compared with usual 
care.5
After conducting a scoping review, we found little 
evidence of cost- effectiveness studies in the UK. The only 
economic evaluation we found in the literature assessed 
the cost- effectiveness of robot- assisted training therapy 
for upper limb rehabilitation within the USA based VA 
Robotics study.6 7 This randomised controlled trial (RCT) 
also assessed the cost- effectiveness of the MIT- Manus 
robotic gym system in upper limb rehabilitation in patients 
who had a stroke. Given the resource intensive nature 
of stroke rehabilitation programmes8 and the lifelong 
impacts of stroke, evidence on the cost- effectiveness of 
these programmes derived from well- designed economic 
evaluations is needed. The RATULS trial is, to our knowl-
edge, the largest and first multicentre trial with sufficient 
statistical power to compare robot- assisted training with 
another evidence- based therapy programme, or usual 
care.9 This paper reports the results from a within- trial 
analysis that formed part of the RATULS trial.
TRIAL OVERVIEW
Summary of RATULS trial
The study was a three- arm RCT which recruited 770 
participants from stroke units, day hospitals, outpatient 
clinics, primary care, community rehabilitation services 
and local stroke clubs in four study centres. The sample 
size calculation yielded a target sample size of 762 partic-
ipants with 216 participants in each group required to 
provide 80% power at a significance level of 1.7%. The 
sample size was revised after protocol publication to 770 
to allow for 15% attrition (rather than 10% as originally 
specified in the published protocol). Full details on 
sample size calculation and trial methodology have been 
reported elsewhere.4 5
Participants were eligible for inclusion in the study if 
they were 18 years or older, had experienced a first- ever 
stroke between 1 week and 5 years prior to randomisa-
tion and, as a consequence of the stroke, had moderate 
or severe upper limb functional limitation as measured 
by the Action Research Arm Test (ARAT)10 (score 0–39). 
Potential participants who had been previously enrolled 
in this study; had participated or were participating in 
another upper limb rehabilitation study; had previously 
used the MIT- Manus robotic gym or another arm rehabil-
itation robot; had other notable upper limb impairment; 
or had a diagnosis that would interfere with the rehabil-
itation or outcome assessments were excluded from the 
trial. All those who were eligible and who consented to 
participate in the study were randomised on a 1:1:1 ratio 
to receive one of the three interventions.
The clinical primary outcome of the study was upper 
limb function ‘success’ using (ARAT)10 at 3 months 
postrandomisation. The definition of success differed 
depending on baseline severity of upper limb functional 
limitation. Success for a baseline ARAT score 0–7 was 
defined as an improvement of 3 points or more; a base-
line ARAT 8–13 required an improvement of 4 points or 
more; baseline ARAT 14–19 required an improvement 
of 5 points or more and finally, a baseline ARAT 20–39 
required an improvement of 6 points or more.4 5 Full 
details of the clinical trial results and methodology have 
been described elsewhere.4 5
Economic evaluation methods
We conducted an economic evaluation consisting of a 
cost–utility analysis using the quality- adjusted life year 
(QALY) as the primary outcome measure following guid-
ance for best practice in health technology appraisal.11
Perspective
We conducted all analyses adopting the perspective of the 
UK National Health Service (NHS) and personal social 
services setting.
Costs
The costs included in the analysis comprised the inter-
vention costs for the robot- assisted training and EULT 
programmes, no intervention costs were directly associ-
ated with usual care and we assumed that any rehabili-
tation received had been reported in the health service 
utilisation questionnaire. We also included use of health 
and social services over the 6- month follow- up period 
for all randomised groups. For the intervention costs we 
assumed, as per the protocol,4 that each therapy session 
in both intervention groups lasted 60 min including 
45 min of face- to- face therapy on a 1:1 basis including the 
same staff component. In addition to staff time, capital 
costs were calculated for robot- assisted training using the 
‘equivalent annual cost’12 methodology applying a 3.5% 
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discount rate and on the basis that the equipment would 
need replacing after 5 years.
We developed a health service utilisation questionnaire, 
informed by previous data collection tools including the 
Client Service Receipt Inventory13 to capture health and 
social care resource use at baseline and 6 months postran-
domisation. At baseline, participants were asked about 
the care received in the 3 months before they joined the 
study. These data were used to control for any imbalance 
in participant use of services at baseline. The informa-
tion collected at 6 months included: visits to accident and 
emergency departments; outpatient appointments; day 
patient appointments; overnight hospital stays; the use of 
general practitioner and nursing services; use of therapy 
services; medications; community- based healthcare; social 
services; and residential care and nursing home stays.
To estimate the cost at 6 months for each participant 
we combined data on use of care and services with unit 
costs obtained from routine data sources. We applied 
NHS national reference costs14 to hospital- based 
services. Information for staff costs, unit costs relating 
to primary care, social care and community health 
services was mostly derived from Curtis and Burns.15 
In order to cost prescribed medication, we collected 
information on medication name, dosage, frequency 
and intake duration. We combined this information 
with unit costs taken from the British National Formu-
lary.16 When information on intake duration, medica-
tion format (eg, dose; mode of intake) was missing, we 
used prescription cost analysis data17 and assumed that 
the participant had been taking the most commonly 
prescribed format and had been issued one prescrip-
tion for the trial period.
We used the information collected at 6- month follow- up 
in addition to the intervention costs to derive the total 
mean cost per participant per each randomised group. 
All costs are reported in pounds Sterling and converted 
to 2018 prices, when appropriate, using the Bank of 
England inflation calculator.18
Effectiveness outcome
The quality of life outcome measures used for the economic 
evaluation were the summary utility scores derived from 
the EQ- 5D- 5L questionnaires.19 These were completed by 
participants at baseline, 3 and 6 months postrandomisa-
tion. The EQ- 5D- 5L questionnaire measures the individu-
al’s self- reported health- related quality of life through the 
following five domains: mobility, self- care, usual activities, 
pain/discomfort and anxiety/depression. Respondents 
were asked to describe each domain according to five 
different levels: no problems, slight, moderate, severe or 
extreme problems. Since there is no currently accepted 
valuation set for the EQ- 5D- 5L questionnaire, we mapped 
the questionnaire responses to the E5- 5D- 3L20 21 descrip-
tive system in order to generate the utility values. These 
utility values formed the basis of our QALY calculations 
using the area- under- the- curve approach.22
Missing data
For the main (base- case) cost- effectiveness analysis we 
only included those participants for whom we had some 
data on costs. Once we determined that missing cost 
data were missing at random, we explored in the sensi-
tivity analyses the effect on cost- effectiveness of applying 
multiple imputation to missing total costs controlling for 
age, sex and baseline ARAT score.
We explored the patterns of missing utility data. Once 
we established that information was missing at random, 
we used multiple imputation methods to estimate the 
missing utility values at 3 months and 6 months. This 
involved applying truncated normal regression while 
controlling for age, sex and baseline ARAT score in order 
to generate the missing utility value.
Base-case cost-effectiveness analysis
We calculated mean costs and effects along with corre-
sponding SD. Where we report differences in mean costs 
and effects between all three randomised groups we 
used 98.33% CIs, as this was a three- arm comparison. We 
conducted all pairwise comparisons using 95% CIs. Using 
seemingly unrelated regression modelling methodology23 
in the adjusted cost- effectiveness analysis, we derived the 
incremental cost per gained QALY for each participant at 
6 months. This approach involved estimating two linear 
regressions with their own dependent variable for costs 
and QALYs and a set of explanatory variables. We used 
randomised group, study centre and time since stroke as 
explanatory variables for both costs and QALYs. Addition-
ally, we incorporated baseline utility scores as an explan-
atory variable for the QALY equation and total baseline 
costs as an explanatory variable to the costs equation. We 
presented the results from the adjusted analysis in the 
form of an incremental cost–effectiveness ratio (ICER). 
The ICER is the difference in mean costs divided by the 
difference in mean effects (in this case QALYs) between 
two alternatives.
In the analysis if a comparator was both more costly 
and less effective than the others it was dropped from any 
further cost- effectiveness comparisons because it was less 
cost- effective than the other comparator.
We created cost- effectiveness acceptability curves in 
order to assess the imprecision surrounding the estimates 
of costs, effects and cost- effectiveness. This approach 
involved drawing bootstrapped samples, with replace-
ment, of the mean costs and mean QALYs from the orig-
inal trial data. We repeated this process increasing the 
number of replications until the results were stable. This 
was achieved at 1000 replications. After using the new 
values generated from the bootstrapping exercise to calcu-
late the difference in costs and effects between groups, we 
combined this information with a range of willingness to 
pay (WTP) values (£0, £10 000, £20 000, £30 000, £50 000) 
per QALY gained. This involved using the net benefit 
statistic24 which multiplied the gain in health (QALYs) 
by the chosen WTP value, the incremental cost was then 
subtracted to obtain the net monetary benefit. We used 
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these results to generate a cost- effectiveness acceptability 
curve which graphically represented the probability of 
each of the interventions being cost- effective at each of 
the prespecified value for society’s WTP for a QALY.25 All 
analyses were carried out in Stata V.15.26
Sensitivity, subgroup and per-protocol analyses
We conducted deterministic sensitivity analyses in order 
to assess the robustness of the cost- effectiveness results for 
three scenarios.
First, we examined the impact of assigning a value of 
zero to missing total healthcare costs.
Second, we examined the possibility that those partic-
ipants with missing total healthcare costs may have used 
some services and hence incurred some costs. Under 
this scenario, once we established that information was 
missing at random, we applied truncated normal regres-
sion methods excluding total costs values below zero and 
above £25 000 (as the highest observed value for total 
costs) and used age, sex and baseline ARAT as covariates.
Finally, we investigated whether increasing the life span 
of the MIT- Manus robotic gym system from 5 to 7 years 
would affect the cost- effectiveness of the interventions.
In order to explore the impact of time since stroke on 
the cost- effectiveness of the interventions, we conducted 
an exploratory analysis for the subgroups outlined in 
the protocol.4 Three subgroups were prespecified (<3 
months, 3–12 months and >12 months) according to time 
since stroke.
A secondary per- protocol cost- effectiveness analysis 
removing from the data set those participants who did 
not receive at least 20 sessions of therapy in the robot- 
assisted training and the EULT programme groups was 
also conducted. The cut- off point of 20 sessions was 
based on clinical evidence that an additional 20 hours 
of therapy compared with control interventions leads to 
improvements on functional outcome.27
We combined each sensitivity, subgroup and per- 
protocol analyses with bootstrapping in order to reflect 
the imprecision surrounding the cost- effectiveness results.
Extrapolation of trial results
We carried out a modelling exercise designed to extrapo-
late the mean QALYs at 6 months to 12 months based on the 
results of the trial, for this, we made a number of assump-
tions. First, we assumed that participants across all groups 
maintained the same utility levels reported at 6 months 
postrandomisation. Second, we considered all inter-
vention costs and therapy- related costs (physiotherapy, 
occupational therapy, and speech and language therapy) 
as sunk costs, since they were deemed not to continue 
beyond the 6- month trial period. However, we assumed 
that all other levels of healthcare resource use remained 
constant from 6 to 12 months postrandomisation.
We calculated the difference in mean costs and effects 
between the randomised groups with differences across 
groups not being formally tested. We used seemingly 
unrelated regression23 methods to calculate the adjusted 
ICER at 12 months including the same explanatory vari-
ables used in the base- case cost- effectiveness analysis. As 
in the base- case analysis we used the bootstrapping tech-
nique to present uncertainty surrounding mean costs, 
effects and cost- effectiveness.
Patient and public involvement
We have designed and reported our research with 
input from stroke survivors. Members from the North 
East Stroke Research Network Patient and Carer Panel 
provided input to the design and content of trial docu-
ments, including health economics questionnaires.
RESULTS
Completeness of data
Most participants (96%) across all groups completed 
the health service utilisation questionnaire at baseline. 
There was a progressive increase in non- responses to 
the health service utilisation questionnaires over the 
6- month follow- up period. The pattern of responses was 
similar across the intervention groups; however, the loss 
to follow- up was more pronounced in the usual care 
group. While completion rates were 83% for the robot- 
assisted training group and 85% for the EULT group, 
this decreased to 70% of usual care participants. Comple-
tion rate of EQ- 5D- 5L at baseline was 99% across all of 
participants. This decreased to 88% at 3 months and 82% 
at 6 months. The highest number of non- responders 
belonged to the usual care group with response rates of 
81% at 3 months and 75% at 6 months.
Health service use and costs
Reported health service resource use was broadly similar 
across all randomised groups at 6 months (table 1). Large 
SD indicate that there was substantial variation in use 
of service between individuals in all three randomised 
groups, with a few participants reporting very high use 
of some services. While not statistically tested, the main 
apparent difference between groups was in the therapy 
services received, with usual care participants receiving 
more home physiotherapy and speech and language 
therapy sessions compared with the robotic- assisted 
training and EULT groups. Participants in usual care had 
a higher reported mean number of contacts with general 
practice and nursing services compared with the robotic- 
assisted training and EULT groups.
The mean total cost per participant for each 
randomised group is reported in table 2. We also report 
the mean total cost per cost category per participant. The 
highest mean costs per participant were associated with 
the use of social care services which included stays in resi-
dential and nursing home facilities and care assistance 
received at home. The average cost per participant was 
higher in the usual care group in all categories except in 
secondary care and other NHS and social services used by 
the participants. The addition of the intervention costs; 
however, reversed this finding making the mean cost per 
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Table 1 Reported health service resource use at 6 months
Area of resource 
utilisation
Robot- assisted training (n=257) EULT (n=259) Usual care (n=254)
Respondents n*
Mean 
contacts (SD) Respondents n*
Mean 
contacts (SD) Respondents n*
Mean contacts 
(SD)
GP surgery 205 1.80 (3.88) 208 1.49 (2.08) 168 1.83 (2.17)
GP home 209 0.37 (1.08) 213 0.27 (0.73) 174 0.38 (1.29)
GP phone 207 0.53 (1.22) 207 0.39 (0.96) 172 0.30 (0.77)
Nurse surgery 203 0.61 (1.39) 210 0.49 (1.19) 169 0.90 (5.58)
Nurse home 206 0.47 (2.07) 213 0.45 (1.65) 170 5.39 (44.63)
Nurse phone 211 0.08 (0.56) 212 0.52 (0.31) 174 0.04 (0.25)
NHS direct 211 0.11 (0.44) 213 0.08 (0.35) 174 0.03 (0.32)
Physiotherapy 
hospital
210 2.18 (6.10) 211 2.99 (9.23) 171 2.64 (7.72)
Physiotherapy 
home




213 0.13 (1.16) 212 0.40 (2.63) 176 0.50 (3.85)
Physiotherapy 
elsewhere
212 0.23 (1.45) 213 0.21 (1.82) 175 0.62 (4.63)
Occupational 
therapy hospital
211 0.64 (3.14) 211 1.23 (7.23) 174 0.57 (3.53)
Occupational 
therapy home
210 1.56 (5.39) 209 1.27 (4.28) 173 1.95 (7.23)
Occupational 
therapy at general 
practice surgery
213 0.00 (0.07) 211 0.01 (0.14) 176 0.02 (0.23)
Occupational 
therapy elsewhere

















213 0.05 (0.42) 213 0.47 (0.68) 175 0.03 (0.45)
A&E visits 213 0.33 (0.77) 214 0.37 (0.98) 178 0.24 (0.70)
Outpatient 
appointments




213 0.79 (4.77) 215 1.83 (12.95) 176 0.70 (3.59)
Hospital nights 
NOT admitted via 
A&E




205 0.08 (0.35) 210 0.09 (0.46) 175 0.06 (0.32)
Continued
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Area of resource 
utilisation
Robot- assisted training (n=257) EULT (n=259) Usual care (n=254)
Respondents n*
Mean 
contacts (SD) Respondents n*
Mean 






199 0.03 (0.17) 201 0.02 (0.18) 169 0.06 (0.07)
Residential care 213 1.75 (14.65) 215 2.08 (17.07) 177 1.39 (10.72)
Nursing home 213 0.00 (0.00) 216 0.83 (12.24) 177 3.08 (23.51)
Meals on wheels 213 0.02 (0.27) 213 0.04 (0.49) 177 0.08 (1.05)
Home help 
personal care
211 2.89 (6.77) 210 3.04 (7.42) 173 3.17 (7.03)
Home help 
household tasks
213 0.74 (3.21) 212 0.68 (3.87) 175 1.06 (4.54)
Home help 
shopping
213 0.11 (0.74) 212 0.07 (0.53) 176 0.11 (0.76)
Health visitor 212 0.05 (0.45) 213 0.09 (0.85) 177 0.03 (0.28)
Geriatrician 212 0.03 (0.42) 213 0.02 (0.23) 177 0.00 (0.00)
Psychiatrist 212 0.13 (0.72) 213 0.75 (0.54) 175 0.01 (0.11)
Psychologist 209 0.45 (2.07) 211 0.28 (1.14) 176 0.44 (2.37)
Chiropodist 210 0.55 (1.19) 210 0.39 (1.06) 173 0.44 (1.02)
Optician 210 0.25 (0.56) 212 0.23 (0.53) 174 0.32 (0.64)
Pharmacist 211 0.66 (2.33) 207 0.60 (2.28) 174 1.16 (4.35)
*n denotes the number of participants who completed all or part of the questionnaire.
A&E, accident and emergency; EULT, enhanced upper limb therapy; GP, general practitioner.
Table 1 Continued
Table 2 Total cost (£) over 6 months for all participants with full economic data
Area of resource utilisation
Robot- assisted training 
(n=257) EULT (n=259) Usual care (n=254)
n Mean (SD) n Mean (SD) n Mean (SD)
Intervention costs 257 2872 (0) 259 1399 (0) 0 –
Primary care costs and 
community- based healthcare 
(including therapy services)
213 743 (1031) 215 777 (1262) 177 1078 (1813)
Social care 213 1410 (3146) 216 1541 (3943) 178 1890 (4281)
Secondary care 213 733 (2247) 216 988 (4486) 178 668 (1880)
Medication costs 157 149 (302) 162 154 (273) 126 198 (347)
Other NHS and social 
services
11 727 (983) 13 790 (946) 9 307 (406)
Deceased participants 1 0 (0) 3 13 953 (4516) 0 –
Mean total cost 257 5387 (4054) 259 4451 (6033) 178 3785 (5437)
Mean difference between 
robot- assisted training and 
usual care with 95% CI; p 
value
1601 (706 to 2496); <0.001
Mean difference between 
EULT and usual care with 
95% CI; p value
665 (−444 to 1774); 0.239
EULT, enhanced upper limb therapy; n, randomised n; NHS, National Health Service.
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participant highest in the group receiving robot- assisted 
training. We found some evidence the mean difference 
in costs between the robot- assisted training group and 
the usual care group was higher (mean difference: 1601 
(95% CI 706 to 2496)). However, there was no evidence 
of a difference between the EULT group and usual care 
higher (mean difference: 665 (95% CI −444 to 1774)).
Health outcomes
The mean utility scores across all randomised groups 
were similar at baseline, 3 months and 6 months as were 
mean QALYs (table 3). The EULT group had the highest 
mean QALY (0.23) followed by robot- assisted training 
and usual care groups, both of which had a mean QALY 
over 6 months of 0.21. The mean differences in QALYs 
between each of the intervention groups (robot- assisted 
training and EULT) and usual care were found to be very 
small and there was no evidence of a difference between 
randomised groups.
Cost-effectiveness analysis, subgroup analysis, per-protocol 
analysis and longer-term model
The base- case cost- effectiveness analysis results (table 4) 
show the adjusted ICER was £74 100 for the comparison 
between EULT and usual care. Robot- assisted therapy 
was, on average, dominated by EULT since it was both, 
on average, more costly and less effective. The cost- 
effectiveness acceptability curve (figure 1), shows that 
EULT had a 19% chance of being cost- effective at the £20 
000 WTP threshold value. The probability of EULT being 
cost- effective remained below 40% at all the WTP values 
considered in the analysis. Robot- assisted training had 
no probability of being cost- effective at all WTP values 
considered in the analysis.
The results from the subgroup analysis are also 
summarised in table 4. These showed that robot- assisted 
training remained dominated on average by EULT in both 
the adjusted and unadjusted results for all subgroups. 
The highest ICER (£126 143) comparing EULT with 
usual care was linked to those participants who had a 
stroke more than 12 months before randomisation. The 
subgroup of participants who were less than 3 months 
poststroke at randomisation had the lowest ICER (£31 
400) for the comparison of EULT with usual care. The 
bootstrapped sensitivity analysis for this group suggested 
that EULT had a 41% probability of being cost- effective at 
the £20 000 WTP threshold.
Results from the per- protocol analysis did not change 
the direction of the cost- effectiveness results. Usual care 
remained the least costly option followed by EULT and 
robot- assisted training. The ICER for EULT and usual 
care was £68 000 and EULT only had a 17% probability 
of being cost effective at the £20 000 WTP threshold. The 
probability of robot- assisted therapy being considered 
cost- effective was very low.
Table 4 shows the results from the economic model 
which extrapolated the trial data on costs and effects to 
12 months. Unadjusted mean costs per participant were 
lowest in the EULT group (£6892) followed closely by 
usual care (£6916) and robot- assisted training (£7538). 
Mean QALYs were in line with those seen in the base- 
case analysis with participants in the EULT group having 
highest mean QALYs at 12 months (0.48) followed by 
usual care (0.47) and robot- assisted training (0.44). 
Once we adjusted for baseline costs, baseline utility score, 
study centre, randomised group and time since stroke, 
usual care reverted to being the least costly option. The 
ICER for the comparison between EULT and usual care 
was £6095, however there was only a 55% probability of 
EULT being considered cost- effective compared with 
usual care at the £20 000 WTP value. Robot- assisted 
training had no probability of being cost- effective at this 
WTP value.
Table 3 Utility scores at baseline, 3 months and 6 months and QALYs at 6 months
Time period
Robot- assisted training 








Baseline EQ- 5D- 5L score 254 0.36 (0.26) 259 0.39 (0.25) 254 0.37 (0.26)
3- month EQ- 5D- 5L score 232 0.45 (0.27) 236 0.48 (0.24) 207 0.42 (0.29)
6- month EQ- 5D- 5L score 223 0.46 (0.29) 222 0.50 (0.27) 190 0.46 (0.27)
QALYs at 6 months after multiple 
imputation
254 0.21 (0.12) 259 0.23 (0.10) 254 0.21 (0.11)
Mean difference in QALYs between 
robot- assisted training and usual 
care with 95% CI; p value
0.00 (−0.20 to 0.20); 0.995
Mean difference in QALYs between 
EULT and usual care with 95% CI; 
p value
0.02 (0.00 to 0.35); 0.080
*n=number randomised.
EULT, enhanced upper limb therapy; QALY, quality adjusted life year.
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Sensitivity analyses
The different scenarios explored in these analyses did 
not change the direction of the results from the base- 
case cost- effectiveness results. Robot- assisted training 
remained dominated on average by EULT in all instances. 
First, when we changed the missing costs to zero, the 
resulting ICER between EULT and usual care increased 
to £172 000. This increase is to be expected since all 
participants with missing total costs belong to the usual 
care group. By imputing zero for missing costs the mean 
costs for the usual care participants decreased and hence, 
when this was done, the ICER increased when compared 
with EULT.
Second, applying multiple imputation methods to 
missing costs resulted in an increase to the unadjusted 
mean usual care costs (£4451) compared with the base- 
case results (£3785). Consequently, the resulting ICER 
from the comparison between EULT and usual care 
decreased to £50 000 with the probability of EULT being 
cost- effective at £20 000 increasing to 27%.
Third, extending the life of the robotic gym system 
resulted in a reduction of the mean capital costs per 
patient and hence, in a lower mean total cost for the 
robot- assisted training group (£5085) compared with the 
base- case analysis (£5387). There were no changes to the 
utility scores across all groups nor to the mean costs for 
EULT and usual care, hence the resulting ICER for the 
comparison of EULT and usual care remained the same 
as in the base- case analysis (£74 100).
DISCUSSION
The RATULS trial found no evidence that robot- assisted 
training, as delivered in the study, improved upper limb 
function ‘success’ for patients who had a stroke with 
moderate or severe upper limb functional limitation 
when compared with a EULT programme or usual care.5 
Our economic evaluation strengthens the evidence base 
of these upper limb rehabilitation programmes through 
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– – – 68 000 0.00 0.17 0.83
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– – – 6095 0.10 0.55 0.35
*98.33% CI used throughout the analyses for the three- arm comparison.
†Data adjusted for baseline costs, baseline utility score, study centre, randomised group and time since stroke.
EULT, enhanced upper limb therapy; ICER, incremental cost–effectiveness ratio; QALY, quality adjusted life year; WTP, willingness to pay.
Table 4 Continued
Figure 1 Cost- effectiveness acceptability curve (base- case 
analysis)—adjusted bootstrapped replications for cost- 
effectiveness analysis. EULT, enhanced upper limb therapy.
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Results from the base- case cost- effectiveness analysis 
suggested that, on average, robot- assisted training was 
more costly than both EULT and usual care and that 
robot- assisted training was slightly less effective than 
EULT. EULT was on average more costly and as effective 
as usual care in the unadjusted analyses and more costly 
and more effective in the adjusted analyses. The balance 
of probabilities favoured usual care as the preferred 
upper limb rehabilitation therapy over the range of 
WTP values considered. Focusing on the society’s WTP 
for a QALY, the bootstrapped analysis suggested that, 
EULT, as delivered in this trial, was unlikely to be cost- 
effective over any of the WTP values considered, despite 
being more effective than robot- assisted training and 
usual care. The subgroup, sensitivity and per- protocol 
analyses did not change the direction of the base- case 
cost- effectiveness results. Extrapolating within- trial 
results to 12 months produced the lowest ICER for 
the comparison between EULT and usual care overall, 
however, high uncertainty surrounds the assumptions 
made about how costs and utilities change beyond the 
trial follow- up.
The main strength of this economic evaluation is that 
it was conducted as part of a rigorously run RCT and 
followed guidelines for best practice throughout.11 28 As 
a result, we were able to base the economic evaluation 
on individual patient data collected during the trial and 
benefited from low levels of missing healthcare resource 
use and quality of life data. However, the loss to follow- up 
in the usual care group may have led to an underestima-
tion of resource use for these participants. Nevertheless, 
when we imputed missing values the results were still 
consistent with those from the base- case analysis.
One of the main challenges in conducting the economic 
evaluation was the difficulty to ascertain the specific 
components of usual care therapy. Log books designed to 
capture detailed usual care information were completed 
by participants. The information gathered was to be used 
alongside the health service utilisation questionnaire. 
Completion rates, however, were very low and we were 
unable to incorporate these data into the economic eval-
uation. We overcame this by drawing on the information 
captured via our primary data collection tool, the health-
care service utilisation questionnaire, where participants 
recorded any therapy sessions received during the trial 
period.
Through the collection of self- reported quality of life 
information at three points during the study using the 
EQ- 5D- 5L questionnaire,19 we were able to measure 
quality of life gains for participants across all groups. One 
strength of this generic tool is that decision makers will 
be able to make priority- setting decisions not only for 
this patient group but across different disease areas.11 
However, the EQ- 5D- 5L questionnaire does not capture 
transitory changes as it only asks about health on the 
day the participant completes it. In addition, this ques-
tionnaire and the QALYs derived from it are not stroke 
specific and it is unknown whether we were able to 
accurately capture changes in quality of life in this patient 
group.
A noteworthy limitation of the economic evaluation is 
associated with the timeframe of the trial. The within- 
trial economic evaluation assessed the cost- effectiveness 
of the interventions at 6 months. A longer- term perspec-
tive was originally planned but due to limitations of the 
data, extrapolation to 12 months only was conducted. 
The results however, need to be interpreted with 
caution due to the assumptions made on both costs and 
utility values.
The economic evaluation fills a significant evidence 
gap with this being the first economic evaluation 
comparing robot- assisted training with usual care having 
been conducted in the UK NHS setting. This evaluation 
expands the analysis conducted on the cost- effectiveness 
of the MIT- Manus robotic system as part of the VA 
Robotics trial.6 7 This study, confined to the US healthcare 
system, reported a small QALY gain for the robot group 
compared with usual care and not significant differences 
in costs between groups. Differences in the healthcare 
system between both countries means that our economic 
evaluation is key for making cost- effectiveness results rele-
vant to the UK NHS setting. Furthermore, it takes into 
account a number of key differences in the design of both 
studies. First, while the VA robotics trial assumed that the 
robotic gym could be used simultaneously by two patients, 
the RATULS trial was designed to deliver robot- assisted 
training on a one- to- one basis. Second, the components 
of the intensive comparison therapy differed in each 
study. Third, we used E5- 5D- 5L as the recommended tool 
to calculate QALYs, while the VA robotic trial calculated 
QALYs from responses to the Health Utility Index Mark 
3 questionnaire.29 All these points reduce the grounds 
for comparability between studies and supports the need 
for the economic analysis we conducted alongside the 
RATULS trial.
The use of multiple sites contributed to the gener-
alisability of the economic evaluation. The analyses 
controlled for differences in sites hence minimising the 
chance of obtaining biased results from differences in 
costs and effects driven by location.
In conclusion, robot- assisted training was not found 
to be cost- effective in comparison to EULT and usual 
care. This economic evaluation suggested that usual 
care remained the most cost- effective type of upper 
limb rehabilitation compared with a EULT therapy 
programme and robot- assisted training for patients 
who had a stroke with moderate or severe functional 
limitation.
The results create opportunities for further research. 
In particular, further research could explore the 
potential effect on both costs and QALYs from recon-
figurations to the delivery of EULT and robot- assisted 
training. It remains unclear, for example, whether deliv-
ering therapy in a group setting may first, be feasible 
in the NHS setting and second improve the quality of 
life and clinical outcomes. Further development of 
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these interventions may increase their cost- effectiveness 
compared with usual care. Additionally, studies with 
a longer follow- up data may help establish whether 
the QALY gains derived from the interventions are 
sustained beyond the set timeframe of the trial, this 
can then lead to a robust assessment of their long- term 
cost- effectiveness.
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